Market Overview

UPDATE: Canaccord Genuity Raises PT to $44 on Aegerion Pharmaceuticals on Encouraging Sales Data

Related AEGR
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
Aegerion Pharmaceuticals Announces Resolution Of Warning Letter for JUXTAPID (lomitapide) Capsules

Canaccord Genuity maintained Aegerion Pharmaceuticals (NASDAQ: AEGR) with a Buy rating and raised the price target from $36.00 to $44.00.

Canaccord Genuity commented, "On the Q4 EPS call, AEGR provided metrics on the first six weeks of the Juxtapid launch in HoFH. The key takeaway was 400+ vs. 1800-targeted U.S. physicians have been REMS-trained (expected to translate into scripts 1-8 weeks post) and have written 85 new scripts globally (“vast majority” in the U.S. – Brazil and Turkey may be active on a named-patient basis). Given the strong early launch progress, we question whether guidance of 250-300 patients on drug exiting 2013 and $15M-25M in 2013 revenue is conservative."

Aegerion Pharmaceuticals closed at $36.12 on Wednesday.

Latest Ratings for AEGR

Aug 2014Deutsche BankMaintainsBuy
May 2014Goldman SachsInitiates Coverage onSell
May 2014Cowen & CompanyDowngradesOutperformMarket Perform

View More Analyst Ratings for AEGR
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Price Target Analyst Ratings


Related Articles (AEGR)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters